Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Roche CEO Grapples with Swiss Franc Surge: Resilient Commitment to U.S. Investment Amidst Challenges
News

Roche CEO Grapples with Swiss Franc Surge: Resilient Commitment to U.S. Investment Amidst Challenges

By adminitfy
April 23, 2026 3 Min Read

Roche has reported a decline in sales for the first quarter of the year, attributing this downturn to the strong Swiss franc and increased generic competition for its older medications. The Swiss pharmaceutical giant’s sales reached 14.7 billion Swiss francs ($18.7 billion), reflecting a 5% drop year-on-year, though it marked a 6% increase when adjusted for constant currency. The appreciation of the Swiss franc against major currencies, particularly the U.S. dollar, significantly impacted the financial results, the company noted.

The strength of the Swiss franc has been notable, having risen 12% against the U.S. dollar last year and continuing to climb by an additional 1% in early 2023. CEO Thomas Schinecker defended the company’s performance, highlighting how one can interpret these figures. He pointed out that while results in Swiss francs showed a decline, sales reported in U.S. dollars actually rose by 9%. “We spend most of our money in the U.S. and have most of our debt there; we’ve also recently acquired another company in the U.S.,” Schinecker stated during an interview on Squawk Box Europe. He emphasized Roche’s commitment to investment in the U.S., viewing it as a non-issue.

Following the earnings announcement, Roche’s shares gained 2% in midmorning trading in Zürich, contributing to a robust 12-month gain of 18%. The company, through its U.S. subsidiary Genentech, has recently engaged in agreements to streamline drug prices for American consumers in exchange for a grace period against proposed tariffs, contingent upon further investments in U.S. manufacturing. Last April, Roche committed to investing $50 billion in the U.S. over the next five years, aiming to create 1,000 direct jobs and an additional 11,000 to bolster its manufacturing capabilities.

The pharmaceutical sector is under pressure as many companies, including Roche, face the upcoming expiration of exclusivity for older drugs, allowing for generic competition to enter the market. To counter this risk, Roche is pursuing both in-house development and strategic acquisitions to enhance future sales. Recent announcements included promising trial results for an experimental multiple sclerosis pill, which significantly reduced relapse rates, although safety concerns lingered.

Looking forward, Roche plans to submit the new medication for FDA approval by mid-2023, with analysts from Barclays indicating a potential for upside despite the concerns. Additionally, Roche is focusing on entering the lucrative weight-loss pharmaceutical market, aiming to secure a spot among the top three players alongside industry leaders Novo Nordisk and Eli Lilly. Schinecker commented in a recent interview that Roche seeks to capture a double-digit market share, noting the market’s early stage and significant potential for growth in addressing weight management.

In Roche’s primary market, the U.S., sales have seen a 5% growth, attributed to successful products like the asthma medication Xolair, the hemophilia treatment Hemlibra, and the blood cancer drug Polivy. The company’s pharmaceutical and diagnostics divisions have reported growth rates of 7% and 3%, respectively. Roche has maintained its full-year sales guidance, targeting mid-single-digit growth for 2026, while anticipating core earnings per share will rise in the high single-digit range under constant currency conditions.

Keywords: Roche, first quarter sales, Swiss franc, generic competition, CEO Thomas Schinecker, investment in U.S., weight-loss pharmaceuticals, FDA approval, earnings growth.

Original Source: https://www.cnbc.com/2026/04/23/roche-stock-earnings-q1-ceo-swiss-franc-us-investment.html
Category :
Tags:
Publish Date: 2026-04-23 15:16:00

Author

adminitfy

Follow Me
Other Articles
IRS Officer's Daughter Dragged by Ex-Help to Use Fingerprint on Safe
Previous

IRS Officer’s Daughter Dragged by Ex-Help to Use Fingerprint on Safe

Next

KAIST Spin-Wave Breakthrough: Cooler, Longer-Lasting Smartphones

Search...

Recent Posts

  • ESPN’s Blockbuster Subscriber Crash Unveiled: 54M Now-Nearly Half Its 2011 Peak-Cord-Cutting Buzz Explained
    by adminitfy
    November 19, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • ESPN’s Blockbuster Subscriber Crash Unveiled: 54M Now-Nearly Half Its 2011 Peak-Cord-Cutting Buzz Explained
  • Horoscope Today, Nov 19, 2026: Your Astrological Predictions Await
  • NASA’s Voyager 1 Hits Record One Light-Day Distance After 50 Years
  • Alleged Russian Agent Arrested for Surveillance of US Tech Firm
  • Anthropic’s IPO and the New Economics of AI Platform Power
  • November 2026 (583)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.